Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review
- PMID: 39264345
- DOI: 10.1097/FTD.0000000000001243
Implementation and Evaluation Strategies for Pharmacogenetic Testing in Hospital Settings: A Scoping Review
Abstract
Background: Pharmacogenetic testing in clinical settings has improved the safety and efficacy of drug treatment. There is a growing number of studies evaluating pharmacogenetic implementation and identifying barriers and facilitators. However, no review has focused on bridging the gap between identifying barriers and facilitators of testing and the clinical strategies adopted in response. This review was conducted to understand the implementation and evaluation strategies of pharmacogenetic testing programs.
Methods: A PRISMA-compliant scoping review was conducted. The included studies discussed pharmacogenetic testing programs implemented in a hospital setting. Quantitative, qualitative, and mixed design methods were included.
Results: A total of 232 of the 7043 articles that described clinical pharmacogenetic programs were included. The most common specialties that described pharmacogenetic implementation were psychiatry (26%) and oncology (16%), although many studies described institutional programs implemented across multiple specialties (19%). Different specialties reported different clinical outcomes, but all reported similar program performance indicators, such as test uptake and the number of times the test recommendations were followed. There were benefits and drawbacks to delivering test results through research personnel, pharmacists, and electronic alerts, but active engagement of physicians was necessary for the incorporation of pharmacogenetic results into clinical decision making.
Conclusions: Further research is required on the maintenance and sustainability of pharmacogenetic testing initiatives. These findings provide an overview of the implementation and evaluation strategies of different specialties that can be used to improve pharmacogenetic testing.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Similar articles
-
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.Pharmacotherapy. 2018 Feb;38(2):205-216. doi: 10.1002/phar.2077. Epub 2018 Jan 21. Pharmacotherapy. 2018. PMID: 29286540
-
Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice.Genes (Basel). 2024 Jul 1;15(7):862. doi: 10.3390/genes15070862. Genes (Basel). 2024. PMID: 39062642 Free PMC article.
-
Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs.Pharmacogenomics. 2021 Apr;22(6):345-364. doi: 10.2217/pgs-2020-0181. Epub 2021 Apr 8. Pharmacogenomics. 2021. PMID: 33829852
-
Implementation of pharmacogenetic testing in pediatric oncology: barriers and facilitators assessment at eight Canadian academic health centres.Pharmacogenomics J. 2024 Nov 19;24(6):36. doi: 10.1038/s41397-024-00356-9. Pharmacogenomics J. 2024. PMID: 39562543
-
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:65-84. doi: 10.1146/annurev-pharmtox-030920-025745. Epub 2020 Oct 2. Annu Rev Pharmacol Toxicol. 2021. PMID: 33006916 Review.
Cited by
-
Patients' Concerns About Receiving Preemptive Pharmacogenomic Testing: Results from a Large, Longitudinal Survey of RIGHT Study Participants.J Pers Med. 2025 Jun 17;15(6):258. doi: 10.3390/jpm15060258. J Pers Med. 2025. PMID: 40559120 Free PMC article.
References
-
- Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy. JAMA. 2004;291:2869–2871.
-
- Borden BA, Lee SM, Danahey K, et al. Point-of-care provider use of pharmacogenomic (PGX) results during prescribing impacts patient (PT) recall of medication recommendations. Clin Pharmacol Ther. 2017;101(suppl 1):S22.
-
- Somogy A. Evolution of pharmacogenomics. Proc West Pharmacol Soc. 2008;51:1–4.
-
- Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.
-
- U.S. Food and Drug Administration. Table of Pharmacogenetic Associations; 2022. Available at: https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogen... . Accessed February 19, 2023.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous